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Translational Relevance
SRC3 is an essential co-activator for the transcriptional activity of ERα and is required for estrogen-dependent cell proliferation. . Analogous to ERα, SRC3 is typically found at enhancer regions involved in long-range regulation of hormonal-responsive genes. In this study we establish the genome-wide chromatin binding preferences for activated SRC3 (SRC3-pS543) in ERα positive breast cancer (BC), as well as the association between SRC3-pS543 expression and clinico-pathological features and clinical outcomes in 1650 primary BCs. Our findings reveal that while ERα and total SRC3 are predominately found in distal enhancers and introns, SRC3-pS543 is predominately located at promoters of genes. SRC3-pS543 was associated with favourable clinic-pathological features, and was found to be an independent prognostic factor as well as a predictive marker with regard to tamoxifen treatment. These observations illustrate that high expression of
Introduction
Oestrogen receptor alpha (ERα) is a key transcription factor in normal breast development and plays a central role in the pathogenesis of ~70% of all breast cancers. Consequently, ERα is recognised as the key therapeutic target in this group of patients (1) . The p160 steroid receptor co-activator (SRC) family member, SRC3 (also known as amplified in breast cancer 1; AIB1) is an essential co-activator for the transcriptional activity of ERα, which recruits SRC3 to chromatin (2) . SRC3 is required for estrogen-driven proliferation of MCF-7 breast cancer cells (3) and is critical for normal mammary development (3) . Overexpression of SRC3 can induce mammary tumorigenesis in mice (4), while its absence protects against breast cancer development (5,6). SRC3 was originally identified as a gene mapping to a region of chromosome 20 (20q12-13), which is frequently amplified in breast cancer and was shown to be amplified in 10% of breast cancers (7). SRC3 mRNA levels are significantly higher in breast cancer as compared to normal mammary tissue (8,9) and SRC3 protein levels are elevated in 16-83% (depending on the study) of human breast tumours (10).
SRC3 expression has been associated with decreased risk of relapse in breast cancer patients who did not receive adjuvant endocrine therapy (11).
Conversely, in tamoxifen-treated patients SRC3 expression was associated with poor outcome and increased risk of relapse (11). Others have found no such association with tamoxifen treatment, although an increased risk was seen with high SRC3 when expressed alongside HER1, HER2 or HER3 (12).
In group of women of whom 82% were postmenopausal, SRC3 expression Author Manuscript Published OnlineFirst on September 14, 2015; DOI: 10.1158/1078-0432.CCR- has been associated with early recurrence on tamoxifen treatment (13), while high SRC3 in pre-menopausal women was an independent predictive factor of improved response to tamoxifen (14) . ERα-associated SRC3 is typically found at enhancer regions, where expression of genes proximal to shared ERα/SRC3 chromatin binding events correlates with poor outcome of ERα positive breast cancer patients treated with tamoxifen (15) . This feature was only found for genes where SRC3 was selectively enriched as compared to the other two p160 family members, SRC1 and SRC2.
Phosphorylation of SRC3 is required for it to function as a potent transcriptional activator, and SRC3 possesses multiple phosphorylation sites that may be functionally involved in this process. (16, 17) . Oestradiol treatment increases SRC3 phosphorylation, but the kinase responsible for this remains elusive. However, a number of kinases are known that induce phosphorylation at these residues of SRC3 (16, 17) . In addition, dephosphorylation of serine-101 and -102 regulates SRC3 protein stability by preventing proteasome-dependent turnover (18) . Of note, the C-terminal domain of SRC3 has weak histone acetyltransferase activity raising the possibility that it may have a role in chromatin remodelling (10).
Previous studies have shown a requirement of SRC3 phosphorylation for SRC3 activity, including phosphorylation of SRC3 at serine residue 543 (SRC3-pS543) (16) . Furthermore, the region around S543 is evolutionarily conserved in mammals, bird and reptiles, while no sequence homology around S543 is found in SRC1 or SRC2 (19). In addition, thus far no studies explored the genomic consequences and clinical significance of SRC3 phosphorylation.Given all the above, we decided to investigate the chromatin 
Material and Methods

Cell lines, plasmids and antibodies.
MCF-7 and CHO cells were from the American Type Culture Collection (ATCC), which utilises short tandem repeat profiling with no authentication being performed by authors. All experiments were performed within 10 passages from the original stock. Cell lines were grown in DMEM with 10% was used, precoupled overnight with 10µg of SRC3 or SRC-pS543 antibody.
Immunoprecipitation was performed overnight while rotating at 4 degrees.
Subsequently, beads were washed 10 times using RIPA buffer and reverse crosslinked at 65 degrees for 6 hours. Supernatant was removed, cleaned using a phenol/chloroform column and precipitated as described before (20 For MCF-7 experiments, ~6x10 7 asynchronous proliferating cells were used, and two independent replicates were performed for each ChIP-seq, where only consensus peaks that were found in both experiments were considered.
For tumour specimen ChIP-seq, fresh snap-frozen primary ERα-positive, HER2-negative untreated breast cancers were obtained from the Imperial
College Healthcare NHS Trust Tissue Bank which has the requisite ethical approval.
Solexa sequencing and enrichment analysis
ChIP DNA was amplified as described (20 (GEO: GSM822392), H3K4me3 (GEO: GSM945269) and H3K27Ac (GEO:
GSM945854) was used. For ERα ChIP-seq data, peaks from (24) were used.
ChIP-seq data for SRC1, SRC2 and total SRC3 were from (15) . For heatmap visualizations, Seqminer software was used.
Motif analysis, heatmaps and genomic distributions of binding events
ChIP-seq data snapshots were generated using the Integrative Genome Motifs datafiles were first generated using Galaxy Cistrome with equal numbers of peaks for each subset, randomly downsamples towards the lowest number. All motifs with p<0.001 were included in the analysis, corresponding to a lower bound absolute z-score of 3.09. Subsequently, motifs for all different genomic datasets were combined in a single radarplot visualization. The genomic distributions of binding sites were analysed using the cis-regulatory element annotation system (CEAS) (26). The genes closest to the binding site on both strands were analysed. If the binding region is within a gene, CEAS software indicates whether it is in a 5′UTR, 3′UTR, coding exon, or an intron. Promoter is defined as 3 kb upstream from RefSeq 5′ start. If a binding site is >3 kb away from the RefSeq transcription start site, it is considered distal intergenic.
Nottingham Tenovus Primary breast cancer Series
Primary operable breast cancer cases (n = 1,650) from the Nottingham Tenovus Primary Breast Carcinoma Series was utilised as described before The peptides were pre-incubated overnight at 100 fold excess over antibody prior to staining as described previously.
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performed using the Cox hazard model. The proportional hazards assumption was tested using standard log-log plots. 
Results
Specificity of SRC3-pS543 Antibody
An antibody for SRC3-pS543 was generated which recognised wild-type phosphorylated SRC3, but not S543-mutated SRC3 (S543A) ( Figure 1A ). The SRC3-pS543 antibody detected SRC3 in immunoprecipitates from MCF-7 cell lysates (Figure 1A , B; full size blot supplementary figure 1 and 2) , where signal was lost after phosphatase treatment ( Figure 1B ). Consistent with a previous report (17) , we find estrogen treatment to increase S543 phopshorylation in a dose-dependent manner, further validating our SRC3-pS543 antibody ( Figure 1C ). To ensure the specificity of the SRC3-pS543 antibody by immunohistochemistry, the antibody was incubated with either peptide containing the phospho-moiety or the non-phospho peptide.
Subsequently, the pre-incubated antibody (bound to non-phospho-peptide and phospho-peptide) was tested on four tumours with different levels of signal for SRC3-pS543 (negative, low/medium, high), Figure 1D . In addition, phosphatase treatment was applied. While the phospho-peptide strongly decreased pS543-SRC3 signal, this was not observed with the non-phospho peptide. In addition, phosphatase treatment strongly diminished pS543-SRC3 signal in all tested specimens ( Figure 1D) .
ChIP-seq analysis shows a genomic preference of SRC3-pS543 to bind promoter regions
Next, we determined the genome-wide distributions of this SRC3- ERα genomic locations, data from (24) were used, while total SRC3 data was from (15) . In total 47,214 ERα binding sites were detected, of which 15, 329 were also bound by SRC3 (15) ( Figure 2B ). Between ERα, SRC3 and SRC3-pS543, 2365 peaks were shared (for raw data visualizations, see Figure 2C ).
Not all SRC3 binding events were phosphorylated and 2795 peaks for SRC3-pS543 were apparently not shared with total SRC3. However, there was weak total SRC3 signal observed at these positions, which did not reach the detection threshold for peak calling (Supplementary Figure S3A and B).
Based on these results, we conclude that differential binding patterns between SRC3-pS543 and total SRC3 should be considered as 'enriched' rather then 'unique'. P160 family members share substantial sequence homology. Even though the sequence surrounding S543 is not conserved in SRC1 and SRC2, the SRC3-pS543 antibody might still detect the other two p160 members. Interestingly, the majority of SRC3-pS543/SRC3 shared peak GO terms, 28 out of 37, were overlapping with those found for the SRC3-pS543 enriched sites, including "metabolic process", "gene expression" and "translation". For a complete list of all GO terms, see Supplementary Table S5 .
Since the SRC3-pS543 chromatin binding events only recapitulated a proportion of the total SRC3 binding events, genomic distributions could deviate as well. As described before (15, 30) , the majority of ERα and SRC3 binding events are found within enhancers and introns ( Figure 2E (4.9%). Furthermore, SRC3-pS543 signal was highly enriched at promoters of E2 regulated genes (31) as compared to all Refseq genes (p<0.0001) ( Figure   2F ).
SRC3-pS543 and ERα chromatin binding events in primary tumour tissue
Next, we determined phosphorylated SRC3/chromatin interactions in primary tumors (Figure 3 ). ChIP-seq was performed on two independent ER+/PR+/HER2-breast tumour specimens as described (21,24), and directly compared with the MCF-7 cell line data. Peak intensities between the two tumours and the MCF-7 sample were comparable, and peaks are wellconserved ( Figure 3A ). Between the two tumours and MCF-7 cells, 2670 binding events of SRC3-pS543 were shared ( Figure 3B , visualized in a raw heatmap in Figure 3C ). Furthermore, peaks were also found selectively enriched for only MCF-7 (2523 sites), tumour #1 (1816 sites) or tumour #2 (4631 sites). The SRC3-pS543 binding sites from all samples were annotated for their genomic distributions, and again enrichment for promoters and 5'UTR regions was found ( Figure 3D ). This was even more strikingly observed for binding events shared by all three samples, with 52% of all sites being localised to promoters and 20% at 5'UTR.
For tumor #1, the lysate was divided in two prior to immunoprecipitation, and the second half of the lysate was used for ERα Furthermore, practically all motifs found at SRC3-pS543 enriched sites were also found at the regions shared by ERα and SRC3-pS543 bounds, including motifs for ELK, ETV and ETS factors as were observed in the MCF7 cells (see Supplementary Table S6 for the total list).
Association of total SRC3 and SRC3-pS543 with clinicopathological features
Total SRC3 and SRC3-pS543 expression was evaluated in 1,650 breast carcinomas, with protein expression predominately nuclear (Supplementary Figure S11) . The total SRC3 mean histoscore was 157 (interquartile range, 0-300) and for SRC3-pS543 mean histoscore was 31 (interquartile range, 0-300). For subsequent analysis, total SRC3 expression was categorized as high (above mean, H-score>157) or low (below mean, H-score<157) and for SRC3-pS543 high (above mean, H-score >31) or low (below mean, H-score Table S3 ). A scatterplot analysis of total SRC3 versus SRC3-pS543 in these tumors shows that the relative levels between total SRC3 versus SRC3-pS543 were strongly variable between tumors. Most importantly, a large proportion of tumors were identified that were positive for total SRC3, but negative for SRC3-pS543. Furthermore, no tumors could be identified that were positive for the phospho-SRC3 but negative for total SRC3, again highlighting specificity of the antibody (Supplementary Figure   S12 ).
While no association on IHC between total SRC3 and ERα was found, there was a strong association for SRC3-pS543 with ERα (p=<0.0001) and high expression of ERα-associated proteins (progesterone receptor; p=<0.0001 and Bcl2; p=<0.0001). Total SRC3 expression was significantly associated with HER2 (p=<0.0001) and HER3 (p=0.023), and correlated the absence of basal-like (p=0.021) and triple negative phenotypes (p=0.005).
( Table 1 ). SRC3-pS543 was significantly associated with well-differentiated 
Association of total SRC3 and SRC3-pS543 expression with outcome
With regard to outcome, no association of total SRC3 with outcome was observed in the whole cohort (Supplemental Figure S11A) , the ERα positive group in total (Supplemental Figure S11B) , or on the basis of tamoxifen treatment (Supplemental Figure S11D , E, F). Furthermore, no association of total SRC3 with outcome was observed in the ERα negative cohort (Supplemental Figure S11C) . However, expression of SRC3-pS543 in the whole cohort was associated with significantly longer disease-free survival 
by 32% (Figure 4G ), whereas for those with high pS543, there was no effect (Figure 4H ), the interaction was statistically significant at (p=0.001). Similarly, exposure to tamoxifen reduced risk of recurrence by 42% (HR (95% CI) = 0.58 (0.44-0.77), p=0.0001) in ER+ high risk patients with low pS543 whereas no effect on those with high pS543 patients, the interaction was statistically significant at (p=0.000.1). Tamoxifen-treated patients with HER2-positive tumours that expressed high levels of SRC3 had a significantly shorter disease free and breast cancer specific survival. This was not observed for the patients who did not receive endocrine treatment (Supplementary Figure   S14 ).
SRC3-pS543 was confirmed as an independent prognostic factor in breast cancers after adjustment for endocrine therapy and other validated prognostic factors; and absence of SRC3-pS543 signal correlated with recurrence (HR=1.4, CI 95%: 1.1-2.5) and death from breast cancer (HR=1.6, CI 95%; 1.1-2.5), ( 
Discussion
Coactivators for ERα have been the focus of many clinical and cell biological studies. SRC3 is of particular interest, since the SRC3 gene is frequently amplified in breast cancer (7), and its expression was found to correlate with HER2 expression levels and poor outcome (11). SRC3 is a member of the p160 coregulator protein family (along with SRC1 and SRC2), which all have shared and preferred genome-wide chromatin binding patterns, which are strongly induced by ERα activation (15) .
Here, we focus on one distinct phosphorylation event on SRC3, Serine 543 phosphorylation. This phosphorylation has spatial selectivity on a genomic scale, where chromatin binding was selectively enriched at active promoter regions. This genomic preference at promoters is on contrast to total SRC3, which is mainly found at enhancers. It is likely that SRC3 and SRC3- to the first report relating SRC3 and response to endocrine therapy (11). The poor outcome seen in HER2-positive/SRC3-high tumours for patients treated with tamoxifen is consistent with previously published data (11,12). One previous study on ERα negative tumours, which utilised automated quantitative analysis (AQUA) in a sub-group of 133 patients, found SRC3 associated with a poorer overall survival (38). However, in the current study of 377 ERα negative tumours no correlations with recurrence or outcome were found for SRC3. Of note, we show a significant correlation of p-JNK and pp38 with SRC3-pS543. These kinases have previously been described to phosphorylate SRC3-S543 (16), and activated (phosphorylated) JNK has previously be linked to endocrine therapy resistance (37) (40), as well as poor outcome in breast cancer (41). The current study linking pJNK with high SRC3-pS543 and a good prognosis group is not comparable with these previous studies for technical and methodological reasons. In the previous study which investigated the expression of pJNK in human breast cancer (39), differing reagents, scoring system as well as a smaller number of cases (n=68) of cases was used. Furthermore, 40% of the cases were ER negative, and in those that were ER positive no clinicopathological correlation was presented (39). While the other studies either investigated the activity of JNK and not its expression in the context of breast cancers exposed to tamoxifen (37) or where levels of pJNK were assessed via immunoblotting in the context of a MCF-7 breast cancer xenograft model (38). Log rank= 2.6, p=0.108
